Which has preferable earnings & valuation, VERU or DERM?

Journey Medical has higher revenue and earnings than Veru. Journey Medical is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veru $16.89M 2.65 -$22.73M -$0.69 N/A Journey Medical $68.18M 3.09 -$11.43M -$0.22 N/A

Is VERU or DERM more profitable?

Veru has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Journey Medical -8.95% -20.23% -6.60%

Does the media favor VERU or DERM?

In the previous week, Journey Medical had 1 more articles in the media than Veru. MarketBeat recorded 3 mentions for Journey Medical and 2 mentions for Veru. Journey Medical's average media sentiment score of 1.52 beat Veru's score of 1.31 indicating that Journey Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Journey Medical 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate VERU or MENS?

Veru presently has a consensus target price of $24.50, indicating a potential upside of 831.56%. Given Veru's stronger consensus rating and higher possible upside, research analysts clearly believe Veru is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veru 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, VERU or MENS?

Jyong Biotech has lower revenue, but higher earnings than Veru. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veru $16.89M 2.65 -$22.73M -$0.69 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is VERU or MENS more profitable?

Jyong Biotech's return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Jyong Biotech N/A N/A N/A

Is VERU or UNCY more profitable?

Veru's return on equity of -47.58% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Unicycive Therapeutics N/A -91.50% -61.47%

Is LENZ or VERU more profitable?

Veru has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. Veru's return on equity of -47.58% beat LENZ Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LENZ Therapeutics -586.74% -53.39% -49.14% Veru N/A -47.58% -35.83%

Does the media favor LENZ or VERU?

In the previous week, LENZ Therapeutics had 4 more articles in the media than Veru. MarketBeat recorded 6 mentions for LENZ Therapeutics and 2 mentions for Veru. Veru's average media sentiment score of 1.31 beat LENZ Therapeutics' score of 1.04 indicating that Veru is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veru 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Veru (VERU) Competitors

$2.63 -0.11 (-4.01%)

As of 08/28/2026 04:00 PM Eastern

Compare

VERU vs. DERM, LFCR, MENS, UNCY, and LENZ

Should you buy Veru stock or one of its competitors? Veru's main competitors and comparable companies include Journey Medical (DERM), Lifecore Biomedical (LFCR), Jyong Biotech (MENS), Unicycive Therapeutics (UNCY), and LENZ Therapeutics (LENZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Veru compare to Journey Medical?

Veru (NASDAQ:VERU) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Veru currently has a consensus price target of $24.50, suggesting a potential upside of 831.56%. Journey Medical has a consensus price target of $14.00, suggesting a potential upside of 87.42%. Given Veru's stronger consensus rating and higher possible upside, analysts clearly believe Veru is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Journey Medical has higher revenue and earnings than Veru. Journey Medical is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.65	-$22.73M	-$0.69	N/A
Journey Medical	$68.18M	3.09	-$11.43M	-$0.22	N/A

In the previous week, Journey Medical had 1 more articles in the media than Veru. MarketBeat recorded 3 mentions for Journey Medical and 2 mentions for Veru. Journey Medical's average media sentiment score of 1.52 beat Veru's score of 1.31 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Journey Medical	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

47.2% of Veru shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 14.2% of Veru shares are owned by company insiders. Comparatively, 14.5% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Veru has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Journey Medical	-8.95%	-20.23%	-6.60%

Veru has a beta of -1.15, meaning that its share price is 215% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Summary

Journey Medical beats Veru on 10 of the 15 factors compared between the two stocks.

How does Veru compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by company insiders. Comparatively, 14.2% of Veru shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Veru had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 2 mentions for Veru and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Veru's score of 1.31 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Lifecore Biomedical	Very Positive
Veru	Positive

Lifecore Biomedical presently has a consensus target price of $6.50, suggesting a potential upside of 43.17%. Veru has a consensus target price of $24.50, suggesting a potential upside of 831.56%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Lifecore Biomedical has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Veru has a beta of -1.15, suggesting that its share price is 215% less volatile than the broader market.

Veru has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Veru	N/A	-47.58%	-35.83%

Veru has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.33	-$40.50M	-$1.07	N/A
Veru	$16.89M	2.65	-$22.73M	-$0.69	N/A

Summary

Veru beats Lifecore Biomedical on 9 of the 16 factors compared between the two stocks.

How does Veru compare to Jyong Biotech?

Veru (NASDAQ:VERU) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, Veru had 1 more articles in the media than Jyong Biotech. MarketBeat recorded 2 mentions for Veru and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Veru's score of 1.31 indicating that Jyong Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Veru	Positive
Jyong Biotech	Very Positive

Veru has a beta of -1.15, indicating that its stock price is 215% less volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market.

Jyong Biotech has lower revenue, but higher earnings than Veru.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.65	-$22.73M	-$0.69	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

47.2% of Veru shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Jyong Biotech's return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Jyong Biotech	N/A	N/A	N/A

Veru presently has a consensus target price of $24.50, indicating a potential upside of 831.56%. Given Veru's stronger consensus rating and higher possible upside, research analysts clearly believe Veru is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Veru beats Jyong Biotech on 7 of the 12 factors compared between the two stocks.

How does Veru compare to Unicycive Therapeutics?

Veru (NASDAQ:VERU) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Veru has higher revenue and earnings than Unicycive Therapeutics. Veru is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.65	-$22.73M	-$0.69	N/A
Unicycive Therapeutics	$680K	215.43	-$26.56M	-$1.75	N/A

Veru currently has a consensus price target of $24.50, indicating a potential upside of 831.56%. Unicycive Therapeutics has a consensus price target of $18.75, indicating a potential upside of 256.46%. Given Veru's higher possible upside, research analysts plainly believe Veru is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Veru had 1 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 2 mentions for Veru and 1 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 1.87 beat Veru's score of 1.31 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Veru	Positive
Unicycive Therapeutics	Very Positive

Veru has a beta of -1.15, indicating that its stock price is 215% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

Veru's return on equity of -47.58% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

47.2% of Veru shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 14.2% of Veru shares are held by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Veru beats Unicycive Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Veru compare to LENZ Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

LENZ Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Veru has a beta of -1.15, meaning that its stock price is 215% less volatile than the broader market.

Veru has lower revenue, but higher earnings than LENZ Therapeutics. Veru is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	8.41	-$82.13M	-$4.09	N/A
Veru	$16.89M	2.65	-$22.73M	-$0.69	N/A

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Comparatively, 14.2% of Veru shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, LENZ Therapeutics had 4 more articles in the media than Veru. MarketBeat recorded 6 mentions for LENZ Therapeutics and 2 mentions for Veru. Veru's average media sentiment score of 1.31 beat LENZ Therapeutics' score of 1.04 indicating that Veru is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENZ Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veru	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LENZ Therapeutics presently has a consensus price target of $28.80, suggesting a potential upside of 463.60%. Veru has a consensus price target of $24.50, suggesting a potential upside of 831.56%. Given Veru's higher possible upside, analysts clearly believe Veru is more favorable than LENZ Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Veru has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. Veru's return on equity of -47.58% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-586.74%	-53.39%	-49.14%
Veru	N/A	-47.58%	-35.83%

Summary

LENZ Therapeutics and Veru tied by winning 8 of the 16 factors compared between the two stocks.

Get Veru News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERU vs. The Competition

Export

Metric	Veru	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$44.76M	$12.15B	$7.20B	$12.91B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-3.81	787.65	273.16	25.45
Price / Sales	2.65	795.07	634.19	94.29
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	1.58	11.97	12.98	6.14
Net Income	-$22.73M	$2.83B	$3.48B	$348.86M
7 Day Performance	-0.38%	0.39%	0.13%	-0.80%
1 Month Performance	18.47%	5.34%	7.08%	4.13%
1 Year Performance	-19.08%	6.05%	24.67%	15.17%

Veru Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERU Veru	3.2643 of 5 stars	$2.63 -4.0%	$24.50 +831.6%	-19.1%	$44.76M	$16.89M	N/A	230	Positive News
DERM Journey Medical	1.8101 of 5 stars	$6.46 -3.9%	$14.00 +116.7%	+3.6%	$185.04M	$68.18M	N/A	90
LFCR Lifecore Biomedical	2.4693 of 5 stars	$4.54 -3.8%	$6.50 +43.2%	-40.3%	$178.67M	$128.87M	N/A	690	Positive News Analyst Downgrade
MENS Jyong Biotech	N/A	$2.01 -0.5%	N/A	-95.7%	$153.58M	N/A	N/A	31	Positive News
UNCY Unicycive Therapeutics	3.2301 of 5 stars	$5.57 +1.1%	$18.25 +227.6%	+25.5%	$153.48M	$680K	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERU) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veru (VERU) Competitors

VERU vs. DERM, LFCR, MENS, UNCY, and LENZ

How does Veru compare to Journey Medical?

Summary

How does Veru compare to Lifecore Biomedical?

Summary

How does Veru compare to Jyong Biotech?

Summary

How does Veru compare to Unicycive Therapeutics?

Summary

How does Veru compare to LENZ Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU vs. The Competition

Veru Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veru (VERU) Competitors

VERU vs. DERM, LFCR, MENS, UNCY, and LENZ

How does Veru compare to Journey Medical?

Do analysts recommend VERU or DERM?

Which has preferable earnings & valuation, VERU or DERM?

Does the media favor VERU or DERM?

Do institutionals & insiders hold more shares of VERU or DERM?

Is VERU or DERM more profitable?

Which has more volatility & risk, VERU or DERM?

Summary

How does Veru compare to Lifecore Biomedical?

Do insiders and institutionals hold more shares of LFCR or VERU?

Does the media prefer LFCR or VERU?

Do analysts recommend LFCR or VERU?

Which has more risk & volatility, LFCR or VERU?

Is LFCR or VERU more profitable?

Which has stronger earnings and valuation, LFCR or VERU?

Summary

How does Veru compare to Jyong Biotech?

Does the media refer more to VERU or MENS?

Which has more volatility & risk, VERU or MENS?

Which has stronger valuation & earnings, VERU or MENS?

Do insiders and institutionals have more ownership in VERU or MENS?

Is VERU or MENS more profitable?

Do analysts rate VERU or MENS?

Summary

How does Veru compare to Unicycive Therapeutics?

Which has better earnings and valuation, VERU or UNCY?

Do analysts rate VERU or UNCY?

Does the media refer more to VERU or UNCY?

Which has more volatility and risk, VERU or UNCY?

Is VERU or UNCY more profitable?

Do institutionals & insiders have more ownership in VERU or UNCY?

Summary

How does Veru compare to LENZ Therapeutics?

Which has more volatility & risk, LENZ or VERU?

Which has better valuation & earnings, LENZ or VERU?

Do insiders and institutionals have more ownership in LENZ or VERU?

Does the media favor LENZ or VERU?

Do analysts rate LENZ or VERU?

Is LENZ or VERU more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU vs. The Competition

Veru Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools